Boucher JC - Search Results

1

Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells.

Boucher JC, Yu B, Li G, Shrestha B, Sallman D, Landin AM, Cox C, Karyampudi K, Anasetti C, Davila ML, Bejanyan N. Boucher JC, et al. J Immunother. 2023 Jan 1;46(1):5-13. doi: 10.1097/CJI.0000000000000445. Epub 2022 Nov 16. J Immunother. 2023. PMID: 36378147 Free PMC article.

2

4-1BB enhancement of CAR T function requires NF-κB and TRAFs.

Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, Davila ML. Li G, et al. Among authors: boucher jc. JCI Insight. 2018 Sep 20;3(18):e121322. doi: 10.1172/jci.insight.121322. eCollection 2018 Sep 20. JCI Insight. 2018. PMID: 30232281 Free PMC article.

3

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.

Shrestha B, Zhang Y, Yu B, Li G, Boucher JC, Beatty NJ, Tsai HC, Wang X, Mishra A, Sweet K, Lancet JE, Kelley L, Davila ML. Shrestha B, et al. Among authors: boucher jc. J Immunother. 2020 Apr;43(3):79-88. doi: 10.1097/CJI.0000000000000306. J Immunother. 2020. PMID: 31834208 Free PMC article.

4

Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.

Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher J, Li G, Ghafoor T, Felices M, Miller JS, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Shrestha B, et al. J Clin Invest. 2020 Sep 1;130(9):4652-4662. doi: 10.1172/JCI135754. J Clin Invest. 2020. PMID: 32437331 Free PMC article.

5

CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.

Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. Boucher JC, et al. Cancer Immunol Res. 2021 Jan;9(1):62-74. doi: 10.1158/2326-6066.CIR-20-0253. Epub 2020 Nov 13. Cancer Immunol Res. 2021. PMID: 33188139 Free PMC article.

6

Chimeric Antigen Receptor Design Today and Tomorrow.

Boucher JC, Davila ML. Boucher JC, et al. Cancer J. 2021 Mar-Apr 01;27(2):92-97. doi: 10.1097/PPO.0000000000000514. Cancer J. 2021. PMID: 33750067 Review.

7

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.

Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. Roselli E, et al. Among authors: boucher jc. J Immunother Cancer. 2021 Oct;9(10):e003354. doi: 10.1136/jitc-2021-003354. J Immunother Cancer. 2021. PMID: 34706886 Free PMC article.

8

Emerging CAR T Cell Strategies for the Treatment of AML.

Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Vishwasrao P, et al. Among authors: boucher jc. Cancers (Basel). 2022 Feb 27;14(5):1241. doi: 10.3390/cancers14051241. Cancers (Basel). 2022. PMID: 35267549 Free PMC article. Review.

9

CD3 engagement as a new strategy for allogeneic "off-the-shelf" T cell therapy.

Li G, Reid KM, Spitler K, Beatty N, Boucher J, Davila ML. Li G, et al. Mol Ther Oncolytics. 2022 Feb 25;24:887-896. doi: 10.1016/j.omto.2022.02.024. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35317526 Free PMC article.

10

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.

Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, Reid K, Spitler K, Yu B, Betts BC, Guevara-Patino JA, Maus MV, Davila ML. Boucher JC, et al. Mol Ther Oncolytics. 2023 Nov 20;31:100751. doi: 10.1016/j.omto.2023.100751. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 38075241 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page